<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796144</url>
  </required_header>
  <id_info>
    <org_study_id>15-1998</org_study_id>
    <secondary_id>1R01DK105526-01A1</secondary_id>
    <nct_id>NCT02796144</nct_id>
  </id_info>
  <brief_title>MEtformin and Lorcaserin for WeighT Loss in Schizophrenia</brief_title>
  <acronym>MELT</acronym>
  <official_title>Metformin and Lorcaserin for Weight Loss in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The purpose of this study is to test new pharmacologic strategies for weight loss in&#xD;
      patients with schizophrenia, a population for which no current weight-loss treatments have&#xD;
      gained widespread use. The goal is to recruit overweight people with schizophrenia to&#xD;
      participate in a 52-week double-blind, randomized study to assess the efficacy and safety of&#xD;
      lorcaserin/metformin combination treatment, lorcaserin monotherapy, and placebo on weight,&#xD;
      body composition, and measures of glucose and lipid metabolism.&#xD;
&#xD;
      Participants: Approximately 110 subjects will be enrolled at four clinical sites (UNC Chapel&#xD;
      Hill, Carolina Behavioral Care, Columbia University, and Augusta University)&#xD;
&#xD;
      Procedures (methods): Behavioral: All participants will be offered a behavioral intervention&#xD;
      of weekly diet and exercise counseling aimed at modifying cardiovascular risk factors. This&#xD;
      intervention will be provided at all in-person study visits after the Baseline Visit and&#xD;
      supplemented with weekly interim phone calls to reinforce lessons between visits.&#xD;
      Pharmacological Intervention: All participants who meet entry criteria will be randomized to&#xD;
      one of the three treatment groups (lorcaserin/metformin, lorcaserin, and placebo).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview of Procedures: All procedures will be conducted at either the UNC Hospitals&#xD;
      outpatient clinic in Chapel Hill, NC, at the outpatient North Carolina Psychiatric Research&#xD;
      Center (NCPRC), a specialized program of the University of North Carolina Center for&#xD;
      Excellence in Community Mental Health in Raleigh, NC, at Carolina Behavioral Care in&#xD;
      Hillsborough, NC, at the Lieber Schizophrenia Research Clinic at the New York State&#xD;
      Psychiatric Institute (NYSPI) in New York, NY, or at Augusta University in Augusta, GA.&#xD;
&#xD;
      Screening: During the initial clinic visit and after giving informed consent, prospective&#xD;
      subjects' psychiatric and medical histories will be reviewed, physical exams conducted,&#xD;
      demographics and vital signs taken, and blood and urine collected. Fasting labs will be&#xD;
      ordered to measure metabolic parameters (lipid profile, glucose, hemoglobin A1C, insulin and&#xD;
      lipids) as well as a complete blood count (CBC), electrolytes, liver/renal function tests,&#xD;
      thyroid stimulating hormone (TSH), urinalysis (UA), serum pregnancy test, and urine drug&#xD;
      screen (UDS). The Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual&#xD;
      of Mental Disorders, Fourth Edition) will be administered to confirm diagnoses and the&#xD;
      Clinical Global Impressions-Severity (CGI-S) will be used to evaluate global psychopathology.&#xD;
&#xD;
      The baseline visit will be scheduled within 28 days of the screening visit. A battery of&#xD;
      assessments will be administered including the Clinical Global Impressions-Severity (CGI-S),&#xD;
      the Alcohol Use Scale (AUS), Drug Use Scale (DUS), Brief Psychiatric Rating Scale (BPRS),&#xD;
      Columbia Suicide Severity Rating Scale (C-SSRS), three assessments to measure eating behavior&#xD;
      (Eating Disorder Examination Questionnaire (EDE-Q), Three-Factor Eating Questionnaire (TFEQ),&#xD;
      and Food Craving Inventory (FCI)). In addition to the paper pencil assessments, a 24 hour&#xD;
      food recall assessment will be administered as a telephone questionnaire by trained personnel&#xD;
      from the UNC Nutrition and Obesity Research Center. Accelerometry will also be used to&#xD;
      estimate subjects' sedentary and active behavior. Dual-Energy X-ray Absorptiometry (DXA) will&#xD;
      also be conducted at the baseline visit (UNC location only). Lastly, the first behavioral&#xD;
      intervention lesson will occur at the baseline visit, providing direct lesson instruction and&#xD;
      a diary for subjects' to take home for recording their homework and progress.&#xD;
&#xD;
      At the completion of the baseline visit, subjects who continue to meet study inclusion&#xD;
      criteria will be randomized to one of the three treatment groups (lorcaserin &amp; metformin,&#xD;
      lorcaserin, and placebo). Lorcaserin will be administered in dosages of 10mg with a maximum&#xD;
      dose of 20mg. Metformin will be administered in dosages of 500mg with a maximum dose of&#xD;
      2,000mg. In addition, matching placebos will be administered for each drug. Doses will be&#xD;
      adjusted based on subject tolerability.&#xD;
&#xD;
      All participants will be offered a behavioral intervention of weekly diet and exercise&#xD;
      counseling aimed at modifying cardiovascular risk factors including weight, activity level,&#xD;
      blood glucose, blood pressure and lipids. This intervention will be provided by a trained&#xD;
      clinician in individualized sessions at all study visits after the Baseline Visit and&#xD;
      supplemented with weekly interim phone calls to reinforce lessons between visits. The&#xD;
      intervention was adapted from a weight-reduction program developed for patients with severe&#xD;
      mental illnesses and was used in the Metformin in the Treatment of Antipsychotic-Induced&#xD;
      Weight Gain in Schizophrenia (METS) and the Clinical Management of Metabolic Problems in&#xD;
      Patients with Schizophrenia: Switching to Aripiprazole versus Continued Treatment with&#xD;
      Olanzapine, Quetiapine, or Risperidone (CAMP) trials and is therefore well known to our&#xD;
      research group and readily implemented as part of the current proposal.&#xD;
&#xD;
      After study enrollment, subjects will be scheduled for a Week 1 and Week 2 study visit. The&#xD;
      purpose of these visits will be to assess medication management (i.e., symptoms, adverse&#xD;
      events/side effects, adherence, adjust dose as indicated), collect vital signs, and provide&#xD;
      the behavioral therapy intervention. The CGI-S will be completed again at both Week 1 and&#xD;
      Week 2, however, the BPRS and C-SSRS will be completed at Week 2 only.&#xD;
&#xD;
      The next 5 study visits will be scheduled as bi-weekly in-person visits. These visits will be&#xD;
      similar to Week 1 and Week, 2 with the addition of the Substance Use Scale and Alcohol Use&#xD;
      Questionnaire. After the first two behavioral intervention sessions, interim telephone calls&#xD;
      will be made between in-person study visits to each participant to reinforce elements of the&#xD;
      program and to answer questions.&#xD;
&#xD;
      After the Week 12 study visit, all in-person study visits will transition to monthly visits&#xD;
      for the rest of the year. The interim telephone calls will be made bi-weekly between the&#xD;
      in-person study visits to each participant to continue to reinforce elements of the program&#xD;
      and to answer questions.&#xD;
&#xD;
      At Week 52, all study measures and fasting labs will be collected again.&#xD;
&#xD;
      Vital signs, adverse events, and side effects will be obtained at all in-person study visits.&#xD;
      Monitoring labs and appetite regulating hormones will be done at Week 12, Week 24, Week 36,&#xD;
      and Week 52.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The FDA advised of a possible health risk associated with lorcaserin and the drug is being&#xD;
    withdrawn.&#xD;
  </why_stopped>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">February 14, 2020</completion_date>
  <primary_completion_date type="Actual">February 14, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Weight in Participants Assigned to Lorcaserin/Metformin Combination Treatment and Placebo</measure>
    <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
    <description>Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight in Participants Assigned to Lorcaserin Monotherapy Treatment and Placebo</measure>
    <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
    <description>Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL Cholesterol</measure>
    <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
    <description>high-density lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol</measure>
    <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
    <description>low-density lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
    <description>serum triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol</measure>
    <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
    <description>Total Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1c</measure>
    <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
    <description>glycosylated hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose</measure>
    <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
    <description>fasting blood glucose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Lorcaserin and Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorcaserin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebos will be administered for each active drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>Max dose of 10 mg BID</description>
    <arm_group_label>Lorcaserin</arm_group_label>
    <arm_group_label>Lorcaserin and Metformin</arm_group_label>
    <other_name>Belviq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Max dose of 1,000 mg BID</description>
    <arm_group_label>Lorcaserin and Metformin</arm_group_label>
    <other_name>Glumetza, Riomet, Glucophage, and Fortamet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebos will be administered for each drug.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients with a diagnosis of schizophrenia or schizoaffective disorder as defined&#xD;
             by DSM-IV-TR criteria (see Appendix 3 and Appendix 4) and confirmed by the Structured&#xD;
             Clinical Interview for DSM-IV (SCID).&#xD;
&#xD;
          -  Duration of psychotic illness must be greater than one year, as defined by having&#xD;
             initiated antipsychotic treatment at least 1 year prior to study enrollment.&#xD;
&#xD;
          -  Must be 18-65 years of age.&#xD;
&#xD;
          -  Must demonstrate adequate decisional capacity to make a choice about participating in&#xD;
             this research study and must provide written informed consent to participate.&#xD;
&#xD;
          -  BMI greater than or equal to 27 kg/m^2&#xD;
&#xD;
          -  Currently treated with one or a combination of two FDA-approved antipsychotic&#xD;
             medications (typical or atypical antipsychotics) AND on that drug regimen for at least&#xD;
             two months prior to study entry (with stable dosages for at least 1 month).&#xD;
&#xD;
          -  Concomitant medications are allowed if agents and doses are unchanged for at least 1&#xD;
             month prior to study entry and if these medications are not among those excluded in&#xD;
             the Exclusion Criteria.&#xD;
&#xD;
          -  Women who can become pregnant must be using an adequate method of contraception to&#xD;
             avoid pregnancy throughout the study and for up to 4 weeks after the study in such a&#xD;
             manner that the risk of pregnancy is minimized. Acceptable methods include oral,&#xD;
             injectable or implanted contraceptives, intrauterine devices or barrier methods such&#xD;
             as condoms, diaphragm and spermicides. Women who can become pregnant must have a&#xD;
             negative serum pregnancy test at the Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inpatient status&#xD;
&#xD;
          -  Clinical Global Impression Severity (CGI-S) score greater than or equal to 6&#xD;
&#xD;
          -  Current treatment with more than 2 antipsychotics&#xD;
&#xD;
          -  HbA1c greater than or equal to 6.5%&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus or current treatment with insulin or oral hypoglycemics&#xD;
&#xD;
          -  Current or prior treatment with metformin within the past 3 months&#xD;
&#xD;
          -  Current or prior treatment with lorcaserin within the past 3 months&#xD;
&#xD;
          -  Current or prior treatment with a 5-HT2B agonist (e.g. cabergoline) within the past 45&#xD;
             days due to potential risk for heart valve defects&#xD;
&#xD;
          -  Current treatment with two or more antidepressants&#xD;
&#xD;
          -  Current treatment with a single antidepressant prescribed in excess of the maximum&#xD;
             approved dose&#xD;
&#xD;
          -  Current treatment with monoamine oxidase inhibitor (MAOI) class of antidepressants&#xD;
             (isocarboxazid, phenelzine, selegiline, tranylcypromine)&#xD;
&#xD;
          -  Concurrent treatment with any of the following pro-serotonergic drugs: meperidine,&#xD;
             buspirone, dextromethorphan, triptans, tramadol, ritonavir, tryptophan, ginseng, St.&#xD;
             John's wort&#xD;
&#xD;
          -  Diagnosis of congestive heart failure&#xD;
&#xD;
          -  Uncorrected thyroid disorder&#xD;
&#xD;
          -  Renal impairment as evidenced by estimated glomerular filtration rate (eGFR) 50&#xD;
             mL/min/1.73 m^2&#xD;
&#xD;
          -  Hepatic disease (ALT, AST, or GGT &gt; 2 times upper limit of normal (ULN), total&#xD;
             bilirubin &gt; 1.2 times ULN)&#xD;
&#xD;
          -  Metabolic acidosis (serum CO2 &lt;20 mEq/L)&#xD;
&#xD;
          -  Known hypersensitivity to metformin or lorcaserin&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Recent (in the past 30 days) or scheduled radiological studies involving iodinated&#xD;
             contrast material&#xD;
&#xD;
          -  Alcohol abuse/dependence as determined by SCID within the past month&#xD;
&#xD;
          -  Other serious and unstable medical condition in the judgment of the investigator&#xD;
&#xD;
          -  DSM-IV diagnosis of mental retardation or dementia&#xD;
&#xD;
          -  Any medication (prescription or non-prescription) used for weight loss must have been&#xD;
             discontinued 3 months prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars F. Jarskog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute (NYSPI), Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Behavioral Care</name>
      <address>
        <city>Hillsborough</city>
        <state>North Carolina</state>
        <zip>27278</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005 Feb;66(2):205-12.</citation>
    <PMID>15705006</PMID>
  </reference>
  <reference>
    <citation>Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS; METS Investigators. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013 Sep;170(9):1032-40. doi: 10.1176/appi.ajp.2013.12010127.</citation>
    <PMID>23846733</PMID>
  </reference>
  <reference>
    <citation>Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.</citation>
    <PMID>21768610</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <results_first_submitted>January 15, 2021</results_first_submitted>
  <results_first_submitted_qc>January 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2021</results_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective disorder</keyword>
  <keyword>overweight</keyword>
  <keyword>obesity</keyword>
  <keyword>weight loss</keyword>
  <keyword>metformin</keyword>
  <keyword>lorcaserin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02796144/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lorcaserin and Metformin</title>
          <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
        </group>
        <group group_id="P2">
          <title>Lorcaserin</title>
          <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lorcaserin and Metformin</title>
          <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
        </group>
        <group group_id="B2">
          <title>Lorcaserin</title>
          <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.52" spread="11.45"/>
                    <measurement group_id="B2" value="43.75" spread="10.16"/>
                    <measurement group_id="B3" value="38.25" spread="9.87"/>
                    <measurement group_id="B4" value="40.85" spread="10.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Weight in Participants Assigned to Lorcaserin/Metformin Combination Treatment and Placebo</title>
        <description>Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks)</description>
        <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin and Metformin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight in Participants Assigned to Lorcaserin/Metformin Combination Treatment and Placebo</title>
          <description>Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks)</description>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.05" spread="2.97"/>
                    <measurement group_id="O2" value="-3.02" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight in Participants Assigned to Lorcaserin Monotherapy Treatment and Placebo</title>
        <description>Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks)</description>
        <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight in Participants Assigned to Lorcaserin Monotherapy Treatment and Placebo</title>
          <description>Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks)</description>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.18" spread="2.43"/>
                    <measurement group_id="O2" value="-3.02" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL Cholesterol</title>
        <description>high-density lipoprotein</description>
        <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
        <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin and Metformin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL Cholesterol</title>
          <description>high-density lipoprotein</description>
          <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.27"/>
                    <measurement group_id="O2" value="1.45" spread="1.71"/>
                    <measurement group_id="O3" value="-0.78" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL Cholesterol</title>
        <description>low-density lipoprotein</description>
        <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
        <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin and Metformin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol</title>
          <description>low-density lipoprotein</description>
          <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.60" spread="3.87"/>
                    <measurement group_id="O2" value="-10.86" spread="5.40"/>
                    <measurement group_id="O3" value="-6.83" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides</title>
        <description>serum triglycerides</description>
        <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
        <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin and Metformin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <description>serum triglycerides</description>
          <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.60" spread="12.86"/>
                    <measurement group_id="O2" value="-19.68" spread="14.97"/>
                    <measurement group_id="O3" value="-3.11" spread="13.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol</title>
        <description>Total Cholesterol</description>
        <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
        <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin and Metformin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol</title>
          <description>Total Cholesterol</description>
          <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.05" spread="3.96"/>
                    <measurement group_id="O2" value="-13.45" spread="7.01"/>
                    <measurement group_id="O3" value="-9.21" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin A1c</title>
        <description>glycosylated hemoglobin</description>
        <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
        <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin and Metformin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c</title>
          <description>glycosylated hemoglobin</description>
          <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.05"/>
                    <measurement group_id="O2" value="0.07" spread="0.08"/>
                    <measurement group_id="O3" value="0.05" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose</title>
        <description>fasting blood glucose</description>
        <time_frame>Baseline, Last Observed Visit (Up to 52 weeks)</time_frame>
        <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Lorcaserin and Metformin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Lorcaserin</title>
            <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose</title>
          <description>fasting blood glucose</description>
          <population>The modified intent to treat (MITT) population included all randomized participants. Analyses using the MITT population were based on subjects with both baseline and post-treatment measures.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.30" spread="3.75"/>
                    <measurement group_id="O2" value="-3.27" spread="2.58"/>
                    <measurement group_id="O3" value="3.53" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time Informed Consent was signed until the last study visit, a total duration of 52 weeks after randomization.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lorcaserin and Metformin</title>
          <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID&#xD;
Metformin: Max dose of 1,000 mg BID</description>
        </group>
        <group group_id="E2">
          <title>Lorcaserin</title>
          <description>Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.&#xD;
Lorcaserin: Max dose of 10 mg BID</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching placebos will be administered for each active drug.&#xD;
Placebo: Matching placebos will be administered for each drug.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized Hives and swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to psychosis exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Important Medical Intervention due to transient suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Excess sweating</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle twitching or spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle stiffness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Problems with coordination</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Racing heart rate</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lars Fredrik Jarskog, MD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-843-7683</phone>
      <email>lars_jarskog@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

